In:
European Journal of Haematology, Wiley, Vol. 67, No. 5-6 ( 2001-11), p. 279-288
Kurzfassung:
Abstract: Background: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60–70% of patients. The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure‐free survival (FFS) to be eligible for investigational treatment is necessary. Objectives: To determine the prognostic significance of the number of involved sites (NIS) in patients with advanced HL and its relationship to the International Prognostic Score (IPS). Methods: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline‐based regimens. The end‐point was FFS. Results: We identified 277 patients with a median age of 32 yr (14–78), 57% of whom were males. AAS was I in 4% of patients, II in 29%, III in 38% and IV in 29%. B‐symptoms were recorded in 81%. Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology. IPS was ≥3 in 44% of 242 evaluable patients. The NIS was ≥5 in 32% of the patients and 20% of all patients had both ≥5 involved sites and IPS ≥3. The 10‐yr FFS was 67%, being 76% vs. 50% for patients with ≤4 vs. ≥5 involved sites ( P 〈 0.0001). The NIS (≥ 5), AAS IV and anemia were independent predictors of FFS in multivariate analysis. The NIS remained significant along with IPS, when the latter was included in the analysis. Patients with ≥5 involved sites and IPS ≥3 had 10‐yr FFS overall, and relapse‐free survival of 41%, 45% and 49%, respectively. Conclusions: The NIS was associated with FFS in advanced HL, was independent of IPS, and led to the identification of a sizeable subgroup of patients with 10‐yr FFS of approximately 40%. This factor should be evaluated during the development of prognostic systems.
Materialart:
Online-Ressource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1034/j.1600-0609.2001.00561.x
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2001
ZDB Id:
2027114-1
Permalink